269 related articles for article (PubMed ID: 15325939)
21. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
Lloret R; Ycas J; Stein M; Haffner S;
Am J Cardiol; 2006 Sep; 98(6):768-73. PubMed ID: 16950182
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
[TBL] [Abstract][Full Text] [Related]
23. Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients.
Liu CS; Lii CK; Chang LL; Kuo CL; Cheng WL; Su SL; Tsai CW; Chen HW
Nutr Res; 2010 Feb; 30(2):118-24. PubMed ID: 20226997
[TBL] [Abstract][Full Text] [Related]
24. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.
John S; Schneider MP; Delles C; Jacobi J; Schmieder RE
Am Heart J; 2005 Mar; 149(3):473. PubMed ID: 15864218
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
Koren MJ; Hunninghake DB;
J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
[TBL] [Abstract][Full Text] [Related]
26. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
[TBL] [Abstract][Full Text] [Related]
27. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
Hirsch M; O'donnell J; Olsson A
Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052
[TBL] [Abstract][Full Text] [Related]
28. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
29. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease.
van der Harst P; Wagenaar LJ; Buikema H; Voors AA; Plokker HW; Morshuis WJ; Six AJ; Boonstra PW; Nickenig G; Wassmann S; van Veldhuisen DJ; van Gilst WH
Am J Cardiol; 2005 Nov; 96(10):1361-4. PubMed ID: 16275178
[TBL] [Abstract][Full Text] [Related]
30. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin.
Murrow JR; Sher S; Ali S; Uphoff I; Patel R; Porkert M; Le NA; Jones D; Quyyumi AA
J Clin Lipidol; 2012; 6(1):42-9. PubMed ID: 22264573
[TBL] [Abstract][Full Text] [Related]
31. Achieving lipid goals in real life: the Dutch DISCOVERY study.
Bots AF; Kastelein JJ;
Int J Clin Pract; 2005 Dec; 59(12):1387-94. PubMed ID: 16351669
[TBL] [Abstract][Full Text] [Related]
32. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
[TBL] [Abstract][Full Text] [Related]
33. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
Wlodarczyk J; Sullivan D; Smith M
Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019
[TBL] [Abstract][Full Text] [Related]
34. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
Dornbrook-Lavender KA; Joy MS; Denu-Ciocca CJ; Chin H; Hogan SL; Pieper JA
Pharmacotherapy; 2005 Mar; 25(3):335-44. PubMed ID: 15843280
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of atorvastatin in patients with severe renal dysfunction.
Holmberg B; Brännström M; Bucht B; Crougneau V; Dimeny E; Ekspong A; Granroth B; Gröntoft KC; Hadimeri H; Ingman B; Isaksson B; Johansson G; Lindberger K; Lundberg L; Mikaelsson L; Olausson E; Persson B; Welin D; Wikdahl AM; Stegmayr BG
Scand J Urol Nephrol; 2005; 39(6):503-10. PubMed ID: 16303728
[TBL] [Abstract][Full Text] [Related]
36. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
37. Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study.
Panichi V; Manca-Rizza G; Paoletti S; Taccola D; Consani C; Sbragia G; Mantuano E; Marchetti V; Carpi A; Barsotti G
Biomed Pharmacother; 2006 Jun; 60(5):249-52. PubMed ID: 16740374
[TBL] [Abstract][Full Text] [Related]
38. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study.
Kawashiri MA; Nohara A; Tada H; Mori M; Tsuchida M; Katsuda S; Inazu A; Kobayashi J; Koizumi J; Mabuchi H; Yamagishi M
Clin Pharmacol Ther; 2008 May; 83(5):731-9. PubMed ID: 17957184
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
[TBL] [Abstract][Full Text] [Related]
40. Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients.
Yamada S; Yanagawa T; Sasamoto K; Araki A; Miyao M; Yamanouchi T
Metabolism; 2006 Jan; 55(1):67-71. PubMed ID: 16324921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
